Armetheon: Stopping the bleeding

Armetheon refocusing anticoagulant tecarfarin on underserved population

Former ARYx Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin three years after the ARYx anticoagulant failed a Phase II/III trial to prevent blood clots. This time around the focus is on chronic use in the narrower population of atrial fibrillation patients with renal insufficiency, a group whose needs aren't met by available therapies.

Tecarfarin (formerly ATI-5923) is a long-acting anticoagulant that inhibits vitamin K epoxide reductase (VKOR). Armetheon acquired

Read the full 777 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE